Trial watch: FDA-approved toll-like receptor agonists for cancer therapy

Keyphrases

• Cancer Therapy 100%
• Toll-like 100%
• FDA-approved Drugs 100%
• Receptor Agonist 100%
• Lipopolysaccharide 66%
• Bacillus Calmette 66%
• Imiquimod 66%
• Phosphoinositide Lipid 66%
• Cancer Cells 33%
• Clinical Trials 33%
• In Situ 33%
• Basal Cell Carcinoma 33%
• Upper Tract Urothelial Carcinoma 33%
• Immune System 33%
• Innate Immune Response 33%
• Tuberculosis 33%
• Double Strand 33%
• Mycobacterium Bovis 33%
• Microbial Component 33%
• Attenuated Strain 33%
• HPV16 33%
• Imidazoquinoline 33%
• Cervarix 33%
• Condyloma Acuminatum 33%
• Actinic Keratosis 33%
• Salmonella Minnesota 33%
• External Genital Warts 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Toll Like Receptor Agonist 100%
• Lipopolysaccharide 66%
• Imiquimod 66%
• Phosphoryl Lipid A 66%
• Toll Like Receptor 66%
• Condyloma acuminatum 66%
• Clinical Trial 33%
• Infectious Agent 33%
• Immunotherapy 33%
• Mycobacterium bovis 33%
• Basal Cell Carcinoma 33%
• Bladder Carcinoma 33%
• Wart Virus Vaccine 33%
• Salmonella Enterica Serovar Minnesota 33%
• Actinic Keratosis 33%
• Human Papillomavirus Type 16 33%